Format

Send to

Choose Destination
Oncotarget. 2014 Jul 30;5(14):5381-91.

Combined therapy with RAD001 e BEZ235 overcomes resistance of PET immortalized cell lines to mTOR inhibition.

Author information

1
Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy; Digestive & Liver Disease Unit, University of La Sapienza, Rome, Italy.
2
Digestive & Liver Disease Unit, University of La Sapienza, Rome, Italy.
3
Department of Biology, University of Rome Tor Vergata, Rome, Italy.
4
Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy; Laboratory of Neuroembryology, Fondazione Santa Lucia, Rome, Italy.

Abstract

Pancreatic endocrine tumors (PETs) are characterised by an indolent behaviour in terms of tumor growth. However, most patients display metastasis at diagnosis and no cure is currently available. Since the PI3K/AKT/mTOR axis is deregulated in PETs, the mTOR inhibitor RAD001 represents the first line treatment. Nevertheless, some patients do not respond to treatments and most acquire resistance. Inhibition of mTOR leads to feedback re-activation of PI3K activity, which may promote resistance to RAD001. Thus, PI3K represents a novel potential target for PETs. We tested the impact of three novel PI3K inhibitors (BEZ235, BKM120 and BYL719) on proliferation of PET cells that are responsive (BON-1) or unresponsive (QGP-1) to RAD001. BEZ235 was the most efficient in inhibiting proliferation in PET cells. Furthermore, combined treatment with BEZ235 and RAD001 exhibited synergic effects and was also effective in BON-1 that acquired resistance to RAD001 (BON-1 RR). Analysis of PI3K/AKT/mTOR pathway showed that RAD001 and BEZ235 only partially inhibited mTOR-dependent phosphorylation of 4EBP1. By contrast, combined therapy with the two inhibitors strongly inhibited phosphorylation of 4EBP1, assembly of the translational initiation complex and protein synthesis. Thus, combined treatment with BEZ235 may represent suitable therapy to counteract primary and acquired resistance to RAD001 in PETs.

PMID:
25026292
PMCID:
PMC4170632
DOI:
10.18632/oncotarget.2111
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center